Memantine Grindeks

Memantine Hydrochloride, the active ingredient in Memantine Grindeks, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, where it helps to reduce excitotoxic neuronal damage and may modestly improve cognition and daily functioning.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders. - Moderate to severe Alzheimer’s disease: improves cognition and daily functioning. - Alzheimer’s disease with behavioral disturbances: may reduce agitation and aggression. - Patients with Alzheimer’s disease who cannot tolerate other therapies: offers an alternative mechanism of action.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatotoxicity - Suicidal thoughts or behavior - Psychosis - Cardiac arrhythmias

When prescribing memantine, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess renal function and monitor for accumulation. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: evaluate risk and monitor neurological status. - Concurrent use with other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and lactation: risk unknown; discuss potential benefits and risks with the patient. - Store at room temperature: keep in the original container, protect from moisture and light.

Memantine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuro‑psychiatric adverse effects. - Ketamine: additive CNS depression and dissociative effects. - High‑dose quinidine: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may enhance hypotensive response. - Anticholinergic drugs: may diminish cognitive benefits of memantine. - Diuretics: risk of dehydration may exacerbate dizziness and confusion.